Stocks crater and go belly up every day especially the leveraged innovative biotechs involved in research and development of new drugs and equipment.. Generex is a special case, however. The extended "blackout" period is inexplicable and inexcusable as shareholders are entitled to accountings. Second, the fact this was a broad-based holding company means losses in one or two areas of investment would be offset by activity in other ventures, creating a buffer to reduce risk associated with companies on a single-track. This, for unknown reason, was not the case.... Third, there has been no revelations from the regulators overseeing this company..... I find that to be strange.